Low dose chloroquine decreases insulin resistance in human metabolic syndrome but does not reduce carotid intima-media thickness

[1]  B. Demir,et al.  The Relationship between Epicardial Adipose Tissue Thickness and Serum Interleukin-17a Level in Patients with Isolated Metabolic Syndrome , 2019, Biomolecules.

[2]  S. Wild,et al.  Ferritin levels throughout childhood and metabolic syndrome in adolescent stage. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  Gina M. Butrico,et al.  Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo , 2018, Nature Medicine.

[4]  A. Avan,et al.  The Relationship Between Vascular Endothelial Growth Factor Cis‐ and Trans‐Acting Genetic Variants and Metabolic Syndrome , 2018, The American journal of the medical sciences.

[5]  S. Moebus,et al.  Comparison of coronary artery calcification, carotid intima-media thickness and ankle-brachial index for predicting 10-year incident cardiovascular events in the general population , 2017, European heart journal.

[6]  B. Becattini,et al.  JNK at the crossroad of obesity, insulin resistance, and cell stress response , 2016, Molecular metabolism.

[7]  M. Amini,et al.  The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition , 2016, Advanced biomedical research.

[8]  G. Bray,et al.  Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. , 2016, The lancet. Diabetes & endocrinology.

[9]  Mark I. McCarthy,et al.  Mendelian Randomization Studies Do Not Support a Causal Role for Reduced Circulating Adiponectin Levels in Insulin Resistance and Type 2 Diabetes , 2013, Diabetes.

[10]  G. Derosa,et al.  Effects of Berberis aristata/Silybum marianum association on metabolic parameters and adipocytokines in overweight dyslipidemic patients. , 2013, Journal of biological regulators and homeostatic agents.

[11]  A. D'Angelo,et al.  Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study , 2013, Inflammation.

[12]  D. McClain,et al.  Iron and diabetes risk. , 2013, Cell metabolism.

[13]  Wendy J Mack,et al.  Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[14]  R. Flavell,et al.  JNK Expression by Macrophages Promotes Obesity-Induced Insulin Resistance and Inflammation , 2013, Science.

[15]  S. Hunt,et al.  Adipocyte iron regulates adiponectin and insulin sensitivity. , 2012, The Journal of clinical investigation.

[16]  D. Bulavin,et al.  Wip1-dependent regulation of autophagy, obesity, and atherosclerosis. , 2012, Cell metabolism.

[17]  D. Solomon,et al.  Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals , 2012, Arthritis Research & Therapy.

[18]  D. Green,et al.  Mitochondrial dysfunction in ataxia-telangiectasia. , 2012, Blood.

[19]  S. Schneeweiss,et al.  Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. , 2011, JAMA.

[20]  Peter Donnelly,et al.  Edinburgh Research Explorer Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes , 2022 .

[21]  C. Vite,et al.  Cholesterol Oxidation Products Are Sensitive and Specific Blood-Based Biomarkers for Niemann-Pick C1 Disease , 2010, Science Translational Medicine.

[22]  Antonio Vidal-Puig,et al.  DNA Damage Links Mitochondrial Dysfunction to Atherosclerosis and the Metabolic Syndrome , 2010, Circulation research.

[23]  Lawrence Joseph,et al.  The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. , 2010, Journal of the American College of Cardiology.

[24]  C. Semenkovich,et al.  p53 is required for chloroquine-induced atheroprotection but not insulin sensitization[S] , 2010, Journal of Lipid Research.

[25]  S. Grundy,et al.  The metabolic syndrome. , 2008, Endocrine reviews.

[26]  H. Wyatt,et al.  Effect of moderate diet-induced weight loss and weight regain on cardiovascular structure and function. , 2009, Journal of the American College of Cardiology.

[27]  T. Buchanan,et al.  Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. , 2008, Atherosclerosis.

[28]  Christopher B. Kendall,et al.  Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[29]  J. Fries,et al.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. , 2007, JAMA.

[30]  R. Vigersky,et al.  A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. , 2007, American heart journal.

[31]  K. Yarasheski,et al.  PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans. , 2006, American journal of physiology. Endocrinology and metabolism.

[32]  J. Schneider,et al.  ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. , 2006, Cell metabolism.

[33]  C. Semenkovich.  Insulin resistance and atherosclerosis. , 2006, The Journal of clinical investigation.

[34]  E. Lander,et al.  Reactive oxygen species have a causal role in multiple forms of insulin resistance , 2006, Nature.

[35]  G. Sumara,et al.  Requirement of JNK2 for Scavenger Receptor A-Mediated Foam Cell Formation in Atherogenesis , 2004, Science.

[36]  H. Kaneto,et al.  Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide , 2004, Nature Medicine.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  R. Haynes,et al.  The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. , 2002, Diabetes research and clinical practice.

[39]  H. Koshiyama,et al.  Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. , 2001, The Journal of clinical endocrinology and metabolism.

[40]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[41]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[42]  L. Powell,et al.  Pathways of intracellular trafficking and release of ferritin by the liver in vivo: The effect of chloroquine and cytochalasin D , 1994, Hepatology.